WO2004101558A1 - 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine - Google Patents

2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine Download PDF

Info

Publication number
WO2004101558A1
WO2004101558A1 PCT/EP2004/004843 EP2004004843W WO2004101558A1 WO 2004101558 A1 WO2004101558 A1 WO 2004101558A1 EP 2004004843 W EP2004004843 W EP 2004004843W WO 2004101558 A1 WO2004101558 A1 WO 2004101558A1
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
morpholin
formula
imidazo
benzothiazol
Prior art date
Application number
PCT/EP2004/004843
Other languages
English (en)
Inventor
Alexander Flohr
Roland Jakob-Roetne
Roger David Norcross
Claus Riemer
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to AU2004238508A priority Critical patent/AU2004238508B2/en
Priority to PL04731369T priority patent/PL1636217T3/pl
Priority to MXPA05012120A priority patent/MXPA05012120A/es
Priority to BRPI0410315-7A priority patent/BRPI0410315A/pt
Priority to JP2006529752A priority patent/JP4408291B2/ja
Priority to DE602004016328T priority patent/DE602004016328D1/de
Priority to EP04731369A priority patent/EP1636217B1/fr
Priority to CA002523959A priority patent/CA2523959A1/fr
Publication of WO2004101558A1 publication Critical patent/WO2004101558A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

L'invention concerne des 2-imidazo-benzothiazoles représentés par la formule générale (I), ainsi que des sels d'addition d'acides pharmaceutiquement acceptables de ces composés. Dans ladite formule, R1 représente un groupe phényle ou un atome d'azote et/ou d'oxygène contenant un hétérocycle et R2 représente un groupe imidazole ou imidazole annelé choisi parmi a), b), c), d) ou e), R3 représentant un atome d'hydrogène ou un groupe phényle, 2,3-dihydro-benzo[1,4]dioxine-6-yle, benzo[b]thiophène-3-yIe, 3-méthyl-benzo[b]thiophène-2-yle, thiophène-2-yle, thiophène-3-yle ou thiophène-2-yl-méthyle, R4 représentant un atome d'hydrogène ou un groupe -(CH2)nO-alkyle inférieur ou alkyle inférieur, R5 représentant un atome d'hydrogène ou un groupe alkyle inférieur, halogène, morpholinyle, -NR'R'', pipéridinyle, éventuellement substitué par hydroxy, ou pyrrolidine-1-yle, R6 représentant un atome d'hydrogène ou un groupe benzyle ou -(CH2)nO-alkyle inférieur et R7 représentant un atome d'hydrogène ou un groupe -C(O)O-alkyle inférieur, -C(O)-C6H4-halogène, -C(O)-C6H4-alkyle inférieur, -C(O)-alkyle inférieur, -C(O)-cycloalkyle, -C(O)-NR'R'', -C(O)-(CH2)nO-alkyle inférieur, -S(O)2-alkyle inférieur, -(CH2)nO-alkyle inférieur, -C(O)-pyridine-4-yle, le noyau pouvant être substitué par alkyle inférieur, halogène-alkyle inférieur ou par pyrrol-1-yl-méthyle, ou représentant -(CH2)n-C(O)-NR'R'', R'/R'' représentant indépendamment un atome d'hydrogène ou un groupe alkyle inférieur ou -(CH2)n-tétrahydropyrane-4-yle, X représentant -CH2-, -NR'''- ou -O-, R''' représentant un atome d'hydrogène ou un groupe -C(O)-alkyle inférieur, -C(O)O-alkyle inférieur, -C(O)-C6H4CH3 ou benzyle et n étant égal à 1 ou 2. Lesdits composés constituent des ligands du récepteur de l'adénosine et sont de ce fait adaptés pour traiter des maladies liées à ce récepteur.
PCT/EP2004/004843 2003-05-13 2004-05-06 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine WO2004101558A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2004238508A AU2004238508B2 (en) 2003-05-13 2004-05-06 Imidazo-benzothiazoles
PL04731369T PL1636217T3 (pl) 2003-05-13 2004-05-06 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
MXPA05012120A MXPA05012120A (es) 2003-05-13 2004-05-06 2-imidazo-benzotiazoles como ligandos de receptores de adenosina.
BRPI0410315-7A BRPI0410315A (pt) 2003-05-13 2004-05-06 2-imidazo-benzotiazóis como ligandos de receptor de adenosina
JP2006529752A JP4408291B2 (ja) 2003-05-13 2004-05-06 アデノシン受容体リガンドとしての２−イミダゾ−ベンゾチアゾール
DE602004016328T DE602004016328D1 (de) 2003-05-13 2004-05-06 2-imidazo-benzothiazole als adenosin-rezeptor liganden
EP04731369A EP1636217B1 (fr) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles constituant des ligands du recepteur de l adenosine
CA002523959A CA2523959A1 (fr) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009842 2003-05-13
EP03009842.0 2003-05-13

Publications (1)

Publication Number Publication Date
WO2004101558A1 true WO2004101558A1 (fr) 2004-11-25

Family

ID=33395778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004843 WO2004101558A1 (fr) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine

Country Status (15)

Country Link
US (1) US7122545B2 (fr)
EP (1) EP1636217B1 (fr)
JP (1) JP4408291B2 (fr)
KR (1) KR100710453B1 (fr)
CN (1) CN100372844C (fr)
AT (1) ATE407133T1 (fr)
AU (1) AU2004238508B2 (fr)
BR (1) BRPI0410315A (fr)
CA (1) CA2523959A1 (fr)
DE (1) DE602004016328D1 (fr)
ES (1) ES2313001T3 (fr)
MX (1) MXPA05012120A (fr)
PL (1) PL1636217T3 (fr)
RU (1) RU2340612C2 (fr)
WO (1) WO2004101558A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086800A1 (fr) * 2006-01-27 2007-08-02 Astrazeneca Ab Nouveaux benzothiazoles substitués par un hétéroaryle
JP2009503114A (ja) * 2005-08-04 2009-01-29 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのベンゾチアゾールおよびチアゾロピリジン
US7670591B2 (en) 2006-06-19 2010-03-02 Astrazeneca Ab Heteroaryl substituted benzoxazoles
US7772256B2 (en) 2007-03-06 2010-08-10 Astrazeneca Ab 2-heteroaryl substituted benzothiophenes and benzofuranes 709
WO2016164565A1 (fr) * 2015-04-08 2016-10-13 University Of Delaware Trans-cycloheptènes et hétéro-trans-cycloheptènes pour couplage bioorthogonal
WO2018193090A3 (fr) * 2017-04-21 2019-01-03 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882797T3 (es) * 2009-04-02 2021-12-02 Merck Serono Sa Inhibidores de dihidroorotato deshidrogenasa
EP2414340A1 (fr) * 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Composés utilisables pour le traitement de troubles à médiation par le récepteur métabotropique 5 au glutamate et leurs procédés d'utilisation
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
BR112020003594A2 (pt) 2017-08-21 2020-09-01 Merck Patent Gmbh derivados de benzimidazol como antagonistas de receptor de adenosina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221444A1 (fr) * 1999-07-02 2002-07-10 Eisai Co., Ltd. Derives d'imidazole condenses et medicaments contre le diabete sucre
US6521754B2 (en) * 2000-06-21 2003-02-18 Hoffman-La Roche Inc. Benzothiazole derivatives with activity as adenosine receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
RU2348622C2 (ru) * 2003-05-21 2009-03-10 Ф.Хоффманн-Ля Рош Аг Производные бензотиазола и их применение при лечении заболеваний, связанных с аденозиновыми а2а-рецепторами

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221444A1 (fr) * 1999-07-02 2002-07-10 Eisai Co., Ltd. Derives d'imidazole condenses et medicaments contre le diabete sucre
US6521754B2 (en) * 2000-06-21 2003-02-18 Hoffman-La Roche Inc. Benzothiazole derivatives with activity as adenosine receptor ligands

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009503114A (ja) * 2005-08-04 2009-01-29 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのベンゾチアゾールおよびチアゾロピリジン
WO2007086800A1 (fr) * 2006-01-27 2007-08-02 Astrazeneca Ab Nouveaux benzothiazoles substitués par un hétéroaryle
CN101410393B (zh) * 2006-01-27 2012-01-25 阿斯利康(瑞典)有限公司 新颖的杂芳基取代的苯并噻唑
US8163928B2 (en) 2006-01-27 2012-04-24 Astrazeneca Ab Heteroaryl substituted benzothiazoles
US8957215B2 (en) 2006-01-27 2015-02-17 Navidea Biopharmaceuticals, Inc. Heteroaryl substituted benzothiazoles
US7670591B2 (en) 2006-06-19 2010-03-02 Astrazeneca Ab Heteroaryl substituted benzoxazoles
US7772256B2 (en) 2007-03-06 2010-08-10 Astrazeneca Ab 2-heteroaryl substituted benzothiophenes and benzofuranes 709
WO2016164565A1 (fr) * 2015-04-08 2016-10-13 University Of Delaware Trans-cycloheptènes et hétéro-trans-cycloheptènes pour couplage bioorthogonal
US10155777B2 (en) 2015-04-08 2018-12-18 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2018193090A3 (fr) * 2017-04-21 2019-01-03 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Also Published As

Publication number Publication date
EP1636217A1 (fr) 2006-03-22
US7122545B2 (en) 2006-10-17
JP4408291B2 (ja) 2010-02-03
US20040229862A1 (en) 2004-11-18
CN1780831A (zh) 2006-05-31
PL1636217T3 (pl) 2009-02-27
ES2313001T3 (es) 2009-03-01
KR20060009928A (ko) 2006-02-01
DE602004016328D1 (de) 2008-10-16
CN100372844C (zh) 2008-03-05
AU2004238508B2 (en) 2009-11-19
KR100710453B1 (ko) 2007-04-24
CA2523959A1 (fr) 2004-11-25
AU2004238508A1 (en) 2004-11-25
RU2005138546A (ru) 2006-07-27
ATE407133T1 (de) 2008-09-15
RU2340612C2 (ru) 2008-12-10
JP2006528215A (ja) 2006-12-14
EP1636217B1 (fr) 2008-09-03
BRPI0410315A (pt) 2006-05-23
MXPA05012120A (es) 2006-02-08

Similar Documents

Publication Publication Date Title
AU2002356626B2 (en) Ureas of 2-aminobenzothiazoles as adenosine modulators
US7371749B2 (en) Benzothiazole derivatives
WO2003010167A1 (fr) Derives de 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine et utilisations de ceux-ci sous la forme de ligands de recepteur d'adenosine
AU2002325316A1 (en) Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1636217B1 (fr) 2-imidazo-benzothiazoles constituant des ligands du recepteur de l adenosine
ZA200509294B (en) Benzothiazole derivatives as adenosine receptor ligands
US6689790B2 (en) Substituted triazolopyridine compounds
US6506772B1 (en) Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
AU2002347055A1 (en) Substituted Triazolopyridine Compounds
AU2002231674A1 (en) Aminotriazolopyridine derivatives as adenosine receptor ligands
CA2520852C (fr) Derives de 7-([1,4]dioxan-2-yl)-benzothiazole utilises comme ligands des recepteurs de l'adenosine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004731369

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004238508

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2523959

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048117819

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2004238508

Country of ref document: AU

Date of ref document: 20040506

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012120

Country of ref document: MX

Ref document number: 2953/CHENP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004238508

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020057021535

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006529752

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005138546

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057021535

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004731369

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410315

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004731369

Country of ref document: EP